SAGE Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Good afternoon. Thank you, everyone, for joining us. We're really pleased to have Sage with us, and we have Barry Greene, CEO of the company. Barry, with that, I'm going to turn it over to you for any opening remarks, and then we can jump in.
Yes. Well, thanks. It's great being and thanks for everyone in the audience for being here. Really quickly, we've got a couple updates. One that came out this morning where we articulated that we were able to accelerate the PPD aspect of the NDA and do 1 filing for both PPD and MDD. We're excited by that because it simplifies the review process. It's better for us, it's better for the agency to have 1 filing. So that was one of the updates this morning.
The second update, which we hadn't updated folks on is that the SHORELINE study is completing enrollment. We were able to roll a majority of the patients from CORAL on the SHORELINE and that allows us to wrap up
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
